teclistamab,talquetamab,daratumumab
genmab,janssen
['redirectt-1']
first dual bi-specific trial results redirectt-11 looking at efficacy and safety. sign of incredible progress in research - but as a patient advocate working in hta, when we have full evidence - how do we get combinations like this to patients? #eha2023 
Director of Research and Advocacy Myeloma UK. 70% work and 30% nonsense. All views my own.